Live price temporarily unavailable.
Belite Bio (BLTE) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$5.74M | −$9.80M | −$12.8M | −$31.7M | −$40.0M | −$84.2M |
| Net income | −$5.75M | −$9.67M | −$12.6M | −$31.6M | −$36.1M | −$77.6M |
| EPS (diluted) | −$0.65 | −$1.01 | −$0.63 | −$1.19 | −$1.18 | −$2.31 |
| Balance sheet | ||||||
| Cash and equivalents | $25.6M | $17.3M | $42.1M | $88.2M | $31.7M | $352.9M |
| Total assets | — | $18.3M | $44.3M | $94.6M | $152.1M | $780.6M |
| Total liabilities | — | $1.64M | $2.77M | $4.21M | $6.31M | $10.1M |
| Shareholders' equity | −$7.04M | −$15.1M | $41.5M | $90.4M | $145.8M | $770.5M |
| Cash flow | ||||||
| Operating cash flow | −$4.44M | −$7.47M | −$11.5M | −$29.8M | −$29.2M | −$37.0M |
| Capital expenditure | — | $74.0K | $394.0K | $63.0K | $116.0K | $71.0K |
| Free cash flow | — | −$7.55M | −$11.9M | −$29.9M | −$29.4M | −$37.1M |
From Belite Bio's 20-F filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
No recent news mentioning Belite Bio in our feed yet.